L. E. Dobrolecki

The interferon/STAT1 signaling axis is a common feature of tumor-initiating cells in breast cancer

The paper identifies an IFN/STAT1 transcriptional state in tumor-initiating cells (TIC) of breast cancer using single-cell RNA sequencing, showing it differs from bulk RNA-seq derived TIC signatures.

BCM PDX Portal: An Intuitive Web-based Tool for Patient-Derived Xenograft Collection Management, as well as Visual Integration of Clinical and Omics Data

The BCM PDX Portal manages PDX collections and integrates clinical and omics data for drug evaluation.

XDec Simplex Map of Breast Cancer Cell States Enables Precise Modeling and Targeting of Breast Cancer

XDec-SM maps breast tumors to a low-dimensional space using bulk RNA-seq, inferring cell states and their associations with mutations and metabolism, and predicting therapy response.

RANK is an independent biomarker of poor prognosis in estrogen receptor-negative breast cancer and a therapeutic target in patient-derived xenografts

This study shows RANK is a poor prognosis biomarker in ER-negative breast cancer and that targeting RANK improves outcomes in patient-derived xenografts.

A Network Approach to Identify Biomarkers of Differential Chemotherapy Response Using Patient-Derived Xenografts of Triple-Negative Breast Cancer

This paper identifies biomarkers of differential chemotherapy response in TNBC using a network-based approach and validates them in PDX models and clinical datasets.

Tumor suppressor PLK2 may serve as a biomarker in triple-negative breast cancer for improved response to PLK1 therapeutics

This study shows PLK2 loss predicts better response to PLK1 inhibitors in triple-negative breast cancer and suggests PLK2 as a biomarker for treatment response.

A breast cancer patient-derived xenograft and organoid platform for drug discovery and precision oncology

The paper develops patient-derived xenografts and organoids for breast cancer to enable drug screening and precision oncology, showing efficacy of an FDA-approved drug in a clinical case.

Heterogeneity in PHGDH protein expression potentiates cancer cell dissemination and metastasis

This study identifies PHGDH protein expression heterogeneity as a driver of breast cancer metastasis by altering metabolic pathways and promoting dissemination.